Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN008 in Healthy Volunteers and Atopic Dermatitis
NCT03798561Phase 1Completed
- Sponsor
- Asana BioSciences, LLC
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Olisutrigine bromide in atopic dermatitis (AD) (7 arms), sponsored by Asana BioSciences, LLC. Primary endpoint: Safety and tolerability of ASN008 topical gel at 22 days. Started Jan 2019; status: completed.
02
Drugs
Olisutrigine bromide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03798561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798561.